Aperture Health Inc (APRE)
followers
·
Follow
Sector:
REAL ESTATE
Industry:
REAL ESTATE
SIC:
OPERATORS OF NONRESIDENTIAL BUILDINGS
CEO:
Employees:
42583 NORTH COYOTE ROAD, QUEEN CREEK, AZ, 85140
973-830-7905
• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Are you looking for this stock instead?
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|